SZSE:002399 (China)
Â
Class A
Â¥
10.9
-0.24 (-2.15%)
Apr 25
What is a stock summary page? Click here for an overview.
Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000P02
Share Class Description:
SZSE:002399: Class ACompare
Compare
Traded in other countries / regions
002399.China09989.Hong KongSHEZF.USA Index Membership
SZSE SME Price IndexSZSE Component IndexCSI 500 Index IPO Date
2010-05-06Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.86 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.29 | |||||
| Debt-to-EBITDA | 4.27 | |||||
| Interest Coverage | 5.34 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.88 | |||||
| Beneish M-Score | -2.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6 | |||||
| 3-Year EBITDA Growth Rate | 18.2 | |||||
| 3-Year EPS without NRI Growth Rate | 41.5 | |||||
| 3-Year Book Growth Rate | 2.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 51.23 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.88 | |||||
| 9-Day RSI | 49.34 | |||||
| 14-Day RSI | 49.05 | |||||
| 3-1 Month Momentum % | 8.93 | |||||
| 6-1 Month Momentum % | -0.98 | |||||
| 12-1 Month Momentum % | 20.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 1.27 | |||||
| Cash Ratio | 0.8 | |||||
| Days Inventory | 568.32 | |||||
| Days Sales Outstanding | 85.69 | |||||
| Days Payable | 33.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 11.36 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 31.38 | |||||
| Operating Margin % | 11.94 | |||||
| Net Margin % | 12.23 | |||||
| FCF Margin % | 31.58 | |||||
| ROE % | 5.33 | |||||
| ROA % | 3.58 | |||||
| ROIC % | 3.85 | |||||
| 3-Year ROIIC % | 116.09 | |||||
| ROC (Joel Greenblatt) % | 9.86 | |||||
| ROCE % | 6.06 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.66 | |||||
| Forward PE Ratio | 21.8 | |||||
| PE Ratio without NRI | 19.78 | |||||
| Shiller PE Ratio | 28.98 | |||||
| Price-to-Owner-Earnings | 38.11 | |||||
| PS Ratio | 3.02 | |||||
| PB Ratio | 1.3 | |||||
| Price-to-Tangible-Book | 1.68 | |||||
| Price-to-Free-Cash-Flow | 9.55 | |||||
| Price-to-Operating-Cash-Flow | 8.61 | |||||
| EV-to-EBIT | 17.88 | |||||
| EV-to-EBITDA | 17.88 | |||||
| EV-to-Revenue | 2.84 | |||||
| EV-to-FCF | 8.99 | |||||
| Price-to-GF-Value | 1.06 | |||||
| Price-to-Projected-FCF | 1.51 | |||||
| Price-to-Median-PS-Value | 0.57 | |||||
| Price-to-Graham-Number | 1.21 | |||||
| Price-to-Net-Current-Asset-Value | 3.46 | |||||
| Earnings Yield (Greenblatt) % | 5.59 | |||||
| FCF Yield % | 11.55 | |||||
| Forward Rate of Return (Yacktman) % | -21.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenzhen Hepalink Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 5,301.711 | ||
| EPS (TTM) (Â¥) | 0.442 | ||
| Beta | 1.5 | ||
| 3-Year Sharpe Ratio | -0.12 | ||
| 3-Year Sortino Ratio | -0.19 | ||
| Volatility % | 38.64 | ||
| 14-Day RSI | 49.05 | ||
| 14-Day ATR (Â¥) | 0.390053 | ||
| 20-Day SMA (Â¥) | 10.933 | ||
| 12-1 Month Momentum % | 20.78 | ||
| 52-Week Range (Â¥) | 8.1 - 12.54 | ||
| Shares Outstanding (Mil) | 1,467.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenzhen Hepalink Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenzhen Hepalink Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shenzhen Hepalink Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399)'s stock price today?
The current price of SZSE:002399 is ¥10.90. The 52 week high of SZSE:002399 is ¥12.54 and 52 week low is ¥8.10.
When is next earnings date of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399)?
The next earnings date of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399) is .
Does Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399) pay dividends? If so, how much?
Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers